Inventiva S.A. (Euronext Paris and Nasdaq: IVA) announced that trading of its ordinary shares on Euronext Paris resumed at approximately 3:30 p.m. CEST (9:30 a.m. ET) on June 2, 2026, following the company's earlier request for a temporary suspension.
The resumption coincides with the earliest time American Depositary Shares (ADSs) are expected to begin trading on the Nasdaq Global Market under the ticker "IVA".
Inventiva is a clinical-stage biopharmaceutical company advancing Lanifibranor, a novel pan-PPAR agonist currently in the pivotal Phase 3 NATiV3 trial for metabolic dysfunction-associated steatohepatitis (MASH).
IVA has traded between $2.85 and $7.98 over the past year. The stock closed Monday's trading at $4.77, down 3.25%. In pre-market trading the stock is at $4.60, down 3.56%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.